The KHNYN Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of the human lung adenocarcinoma cell line NCI-H1975, engineered to disrupt the KHNYN gene. This polyclonal knockout product provides a heterogeneous pool of cells with targeted gene disruption, suitable for functional studies of KHNYN in RNA biology and cancer. Researchers can utilize this model to examine the consequences of KHNYN loss on transcriptome dynamics without the limitations of single-cell clone selection.
The host cell line, NCI-H1975, is a widely used non-small cell lung cancer (NSCLC) model derived from a female patient with lung adenocarcinoma. These cells harbor activating EGFR L858R and T790M mutations, rendering them dependent on EGFR signaling and resistant to first-generation tyrosine kinase inhibitors. The NCI-H1975 background is particularly relevant for investigating mechanisms of acquired drug resistance and for testing targeted therapies against mutant EGFR.
KHNYN encodes a putative RNA-binding protein with endoribonuclease activity, involved in mRNA processing and stability. It likely participates in RNA degradation and miRNA biogenesis, interacting with RNA molecules and possibly components of the RNA exosome. Representative pathway components linked to KHNYN include DICER1 and AGO2, key factors in miRNA maturation and function. Mechanistically, KHNYN influences post-transcriptional regulation by cleaving or processing RNA targets, thereby modulating mRNA and miRNA expression. Its disruption may dysregulate oncogenic signaling networks in NSCLC cells.
In the context of NCI-H1975 cells, KHNYN knockout provides a powerful tool to dissect how RNA regulatory pathways contribute to lung adenocarcinoma progression and drug resistance. Given the EGFR mutation background, this model enables investigation of interactions between oncogenic kinase signaling and post-transcriptional gene regulation. Researchers can explore whether KHNYN loss sensitizes cells to osimertinib or other EGFR inhibitors, or whether it impacts epithelial-mesenchymal transition and metastatic potential.
Typical applications include RNA sequencing to map transcriptomic changes, RT-qPCR validation of candidate mRNA and miRNA targets, and western blotting to assess EGFR pathway activity. Cell proliferation, apoptosis, and drug sensitivity assays (e.g., osimertinib) are used to evaluate functional consequences of KHNYN disruption. This model supports screening for novel RNA regulators in NSCLC drug resistance. For further information or customized requests, please contact Ascent Research.
